Article info
Clinical science
Prognostic factors of 2-year outcomes of ranibizumab therapy for polypoidal choroidal vasculopathy
- Correspondence to Dr Taiichi Hikichi, Ohtsuka Eye Hospital, Kita-16 Nishi-4, Kita-ku, Sapporo 001-0016, Japan; taiichi-hikichi{at}hokkaido.med.or.jp
Citation
Prognostic factors of 2-year outcomes of ranibizumab therapy for polypoidal choroidal vasculopathy
Publication history
- Received May 28, 2014
- Revised November 4, 2014
- Accepted November 19, 2014
- First published December 5, 2014.
Online issue publication
May 25, 2016
Article Versions
- Previous version (25 May 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions